Clinical Trials Logo

Dystrophic Epidermolysis Bullosa clinical trials

View clinical trials related to Dystrophic Epidermolysis Bullosa.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04917874 Completed - Clinical trials for Recessive Dystrophic Epidermolysis Bullosa

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Start date: May 25, 2021
Phase: Phase 3
Study type: Interventional

This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase 3 study, as well as, new participants who were unable to participate in the Phase 3 study, who meet all enrollment criteria.

NCT ID: NCT04491604 Completed - Clinical trials for Recessive Dystrophic Epidermolysis Bullosa

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

GEM-3
Start date: August 17, 2020
Phase: Phase 3
Study type: Interventional

To determine whether administration of topical B-VEC improves wound healing as compared to placebo, and to evaluate durability, repeat dosing (Primary Endpoint) and further obtain safety and tolerability data.

NCT ID: NCT03536143 Completed - Clinical trials for Dystrophic Epidermolysis Bullosa

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

GEM-1
Start date: May 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study was conducted to assess the safety and efficacy of topical Beremagene Geperpavec (KB103, HSV1-COL7) on DEB patients.

NCT ID: NCT03472287 Completed - Clinical trials for Dystrophic Epidermolysis Bullosa

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Start date: May 18, 2018
Phase: Phase 1
Study type: Interventional

A pharmacokinetic (PK) study in 16-20 EB subjects to be allocated to two cohorts. Cohort 1 to include 8-10 subjects (ages 12 yrs and older); Cohort 2 to include 8-10 subjects (ages 6 months-11 yrs, inclusive). Cohort 2 only included subjects 4 yrs and older. Serial PK blood sampling collected on Days 1 and 10. Analyses were performed to determine the concentrations of diacerein and rhein.

NCT ID: NCT03183934 Completed - Clinical trials for Dystrophic Epidermolysis Bullosa

A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial

Start date: December 8, 2017
Phase:
Study type: Observational

This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1/2 clinical trial(ALLO-ASC-EB-101) for 24 months.

NCT ID: NCT02579369 Completed - Clinical trials for Dystrophic Epidermolysis Bullosa

Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Start date: December 8, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Dystrophic Epidermolysis Bullosa.

NCT ID: NCT02178969 Completed - Clinical trials for Dystrophic Epidermolysis Bullosa

Short Term Observational Study in DEB Patients

Start date: June 24, 2014
Phase:
Study type: Observational

The purpose of this study is to better understand disease extent and to identify appropriate methodologies to evaluate (dystrophic epidermolysis bullosa) DEB in a quantitative and qualitative manner.

NCT ID: NCT01538862 Completed - Clinical trials for Dystrophic Epidermolysis Bullosa

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

Start date: February 2012
Phase: N/A
Study type: Interventional

This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is effective as a treatment of Dystrophic Epidermolysis Bullosa (EB.) Patients will receive one course of treatment with the study drug. The course will be 7 days in length. After receiving GCSF, patients will be followed at 7 and 30 days following the discontinuation of the drug. Thirty day follow up can be done via telephone communication with the patient or family.